Our Mission
ARDAN PHARMA aims to revolutionize cancer treatment by developing therapies that boost the innate immune system and overcome tumor resistance.
Disruptive discoveries by our founders prompted us to the search for translational tools that allow us to provide patients with better therapies.
Why are we different?
First in class portfolio
Novel target associated with Immunotherapy resistance and poor overall survival
Unleashes inflammation and malignant Cell Death
Overcomes immunotherapy and targeted therapies resistance
Our Approach
ARDAN’s scientific team has over ten years of exhaustive study on Immune System Modulation. By unleashing inflammatory pathways, our compounds trigger strong anti-tumoral immunity
in several in vivo models such as: melanoma, lymphoma, colon and lung cancer. Moreover, ARDAN’s compounds induce inflammasome-dependent cell death in human primary leukemic cells. Our technology has synergistic effects with immunotherapies based on the blockade of Immune Checkpoint Blockers, as well as with Bcl-2 antagonists.
We are committed to transform the treatment of cancer by developing and validating first-in class compounds that target emerging molecular pathways.
